EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells

Haixin Zhu, Gezi Yan, Junjie Ma, Bo Zhang, Youyou Yan, Lulin Zhu, Rong Dong, Nengming Lin, Biqin Tan

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04799-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Haixin Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, 311402, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, Hospital Pharmaceutical Research Fund Project of Zhejiang Provincial Pharmaceutical Association, the Medical and Health Science and Technology Plan Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsHumansApoptosisHT29 CellsMutationFluorouracilCell ProliferationHeterocyclic Compounds, 3-RingAntineoplastic Combined Chemotherapy Protocolsraf KinasesSulfonamidesDiphenylamine

Stichwörter der Autor:innen

5-FUColorectal cancer (CRC)VS6766p-ERKp-MEK

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanProtein Kinase InhibitorsFluorouracilHeterocyclic Compounds, 3-RingMK 2206N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamideraf KinasesSulfonamidesDiphenylamine

Autor:innen und Institutionen

  • College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, 311402, China.
  • Department of Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006…
  • Westlake Laboratory of Life Sciences and Biomedicine of Zhejiang Province, Hangzhou, 310024, China.
  • Cancer Center, Zhejiang University, Hangzhou, 310058, China.
  • College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, 311402, China. dongrongdrdr@zju.edu.cn.
  • College of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, 311402, China. lnm1013@163.com.

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • Hospital Pharmaceutical Research Fund Project of Zhejiang Provincial Pharmaceutical Association
  • the Medical and Health Science and Technology Plan Project of Zhejiang Province

Zitieren

APA

Zhu, H., Yan, G., Ma, J., Zhang, B., Yan, Y., Zhu, L., Dong, R., Lin, N., & Tan, B. (2025). Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04799-0

Vancouver

Zhu H, Yan G, Ma J, Zhang B, Yan Y, Zhu L, et al. Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04799-0

BibTeX
@article{Zhu2025,
  author = {Zhu, Haixin and Yan, Gezi and Ma, Junjie and Zhang, Bo and Yan, Youyou and Zhu, Lulin and Dong, Rong and Lin, Nengming and Tan, Biqin},
  title = {Anti-tumor efficacy of RAF/MEK inhibitor VS6766 in KRAS-mutated colorectal cancer cells},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04799-0}
}
Kostenlos starten →